World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
24925
World Ranking
13282
National Ranking
6762

Overview

John J. Wright is affiliated with the National Institutes of Health in the United States. Their research primarily focuses on areas within biochemistry, genetics, and molecular biology, with significant contributions in medicine. The scientist's work spans several subfields, including molecular biology, oncology, biophysics, renewable energy, sustainability and the environment, and pulmonary and respiratory medicine.

The main topics addressed in their research include photosynthetic processes and mechanisms, ATP synthase and ATPases research, mitochondrial function and pathology, electron spin resonance studies, lipid membrane structure and behavior, metalloenzymes and iron-sulfur proteins, and acute myeloid leukemia research.

John J. Wright has published extensively in a variety of academic venues. The most frequent publication outlets are:

  • Nature Communications
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood
  • Chemistry - A European Journal
  • Current Opinion in Structural Biology

Their recent papers include:

  • Structure of inhibitor-bound mammalian complex I, 2020, Nature Communications
  • Cryo-EM structures define ubiquinone-10 binding to mitochondrial complex I and conformational transitions accompanying Q-site occupancy, 2022, Nature Communications
  • Functional basis of electron transport within photosynthetic complex I, 2021, Nature Communications
  • Making the leap from structure to mechanism: are the open states of mammalian complex I identified by cryoEM resting states or catalytic intermediates?, 2022, Current Opinion in Structural Biology
  • Reverse Electron Transfer by Respiratory Complex I Catalyzed in a Modular Proteoliposome System, 2022, Journal of the American Chemical Society

This scientist has collaborated frequently with several researchers, demonstrating a pattern of ongoing scientific partnerships. Frequent co-authors include:

  • Judy Hirst
  • Maxie M. Roessler
  • Daniel N. Grba
  • Hannah R. Bridges
  • Injae Chung

Best Publications

  • Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Richard L. Piekarz;Robin Frye;Maria Turner;John J. Wright

  • Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

    Owen A. O'Connor;John Wright;Craig Moskowitz;Jamie Muzzy

  • Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

    Richard T. Kloos;Matthew D. Ringel;Michael V. Knopp;Nathan C. Hall

  • Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

    Judith E. Karp;Jeffrey E. Lancet;Scott H. Kaufmann;David W. End

  • Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

    Richard L. Piekarz;Robin Frye;H. Miles Prince;Mark H. Kirschbaum

  • A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

    John C. Byrd;Guido Marcucci;Mark R. Parthun;Jim J. Xiao

  • Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

    William L. Dahut;James L. Gulley;Philip M. Arlen;Yinong Liu

  • Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

    Elaine T. Lam;Matthew D. Ringel;Richard T. Kloos;Thomas W. Prior

  • Sorafenib for Advanced and Refractory Desmoid Tumors.

    Mrinal M. Gounder;Michelle R. Mahoney;Brian A. Van Tine;Vinod Ravi

  • Clinical Toxicities of Histone Deacetylase Inhibitors.

    Srividya Subramanian;Susan E. Bates;John J. Wright;Igor Espinoza-Delgado

  • Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

    Nilofer S. Azad;Edwin M. Posadas;Virginia E. Kwitkowski;Seth M. Steinberg

  • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

    Ravi A Madan;Mahsa Mohebtash;Philip M Arlen;Matteo Vergati

  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

    James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang

  • Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

    Shivanni Kummar;Helen X. Chen;John Wright;Susan Holbeck

  • Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

    Ashraf Badros;Angelika M. Burger;Sunita Philip;Ruben Niesvizky

  • Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer

    Alex A. Adjei;Ann Mauer;Laura Bruzek;Randolph S. Marks

  • Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.

    Richard L. Piekarz;A. Robin Frye;John J. Wright;Seth M. Steinberg

  • A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer

    Geoffrey I. Shapiro;Jeffrey G. Supko;Angus Patterson;Cathy Lynch

  • Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

    Gautam Borthakur;Hagop Kantarjian;Farhad Ravandi;Weiguo Zhang

  • Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

    Melissa Alsina;Rafael Fonseca;Edward F. Wilson;A. Nelida Belle

Frequent Co-Authors

William D. Figg
William D. Figg National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
James L. Gulley
James L. Gulley National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
Judith E. Karp
Judith E. Karp Johns Hopkins University
Joseph A. Sparano
Joseph A. Sparano Albert Einstein College of Medicine
B. Douglas Smith
B. Douglas Smith Johns Hopkins University
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
Jorge E. Cortes
Jorge E. Cortes Augusta University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical education in the USA can open doors to a variety of healthcare career options, especially with the growth of accessible online degree programs. Many students and working professionals are seeking cost-effective solutions, such as the cheapest bsn programs online, which allow for flexible learning while minimizing debt.

For registered nurses aiming to expand their qualifications, knowing what is the cheapest rn to bsn program online is crucial. These bridge programs are designed to be completed quickly and affordably, helping nurses advance their roles within the healthcare system.

Those pursuing leadership, advanced research, or academic careers may consider online phd nursing programs. Such degrees provide flexibility and specialized knowledge for high-level positions.

Additionally, career changers with non-nursing backgrounds can enter the profession through online msn programs for non nurses. These pathways offer direct progression into master’s-level nursing, preparing graduates for advanced practice or management roles.

Exploring these online pathways ensures you find the right fit—both academically and financially—on the road to a rewarding healthcare career.

Best Scientists Citing John J. Wright

Trending Scientists